ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > TGF-beta RI

TGF-beta RI

概要

Name:Transforming growth factor beta receptor 1
Target Synonym:EC 2.7.11,TGF-beta type I receptor,Serine/threonine-protein kinase receptor R4,TGFBR1,Activin A receptor type II-like protein kinase of 53kD,Transforming Growth Factor Beta Receptor 1,Transforming Growth Factor-Beta Receptor Type I,Activin A Receptor Type II-Like Kinase, 53kDa,Activin Receptor-Like Kinase 5,TGFR-1,ALK-5,ALK5,SKR4,Mutant Transforming Growth Factor Beta Receptor I,TGF-Beta Receptor Type-1,TGF-Beta Receptor Type I,EC 2.7.11.30,ACVRLK4,LDS1A,LDS2A,AAT5,LDS1,TBRI,ESS1,MSSE,TbetaR-I,T
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Phase 2 Clinical

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
TG1-H5254 Human Human TGF-beta RI Protein, Fc Tag (MALS verified)
TG1-H5254-structure
TG1-H5254-sds
TG1-H5259 Human Human TGFR-1 / ALK-5 / TGF-beta receptor type-1 Protein, Llama IgG2b Fc Tag (SPR verified)
TG1-H5259-structure
TG1-H5259-sds
ACRO Quality

生物活性データの一部

TG1-H5254-SPR
 TGF-beta RI SPR

Human TGFB1, premium grade (Cat. No. TG1-H4212) immobilized on CM5 Chip can bind Human TGF-beta RI Protein, Fc Tag (Cat. No. TG1-H5254) with an affinity constant of 99.2 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

TG1-H5259-SPR
 TGF-beta RI SPR

Biotinylated Human TGF-Beta 1, Avitag (Cat. No. TG1-H8217) immobilized on SA Chip can bind Human TGF-beta RI, Llama IgG2b Fc Tag (Cat. No. TG1-H5259) with an affinity constant of 83.7 nM as determined in a SPR assay (Biacore 8K) (QC tested).

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Galunisertib LY-2157299 Phase 2 Clinical Eli Lilly And Company Breast Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Peritoneal Neoplasms; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Solid tumours; Neoplasms; Myelodysplastic Syndromes; Glioblastoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Liver Neoplasms Details
GF-101 GFH-018; GF-101; GFH018 Phase 2 Clinical Genfleet Therapeutics (Shanghai) Inc Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung Details
ORG-129 ORG-129; AGMB-129 Phase 2 Clinical Origo Biopharma Sociedad Litmitada Crohn Disease Details
TRK-250 TRK-250; BNC-1021 Phase 1 Clinical Bonac Corp Idiopathic Pulmonary Fibrosis Details
Itacnosertib TP-0184 Phase 1 Clinical Tolero Pharmaceuticals Inc, Sumitomo Dainippon Solid tumours; Anemia Details
Oxinseti SH-3051 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Solid tumours; Liver Neoplasms Details
AGMB-447 AGMB-447; ORG-447 Phase 1 Clinical AgomAb Therapeutics NV Idiopathic Pulmonary Fibrosis Details
TD-1058 Phase 1 Clinical Theravance Biopharma Inc Idiopathic Pulmonary Fibrosis Details

This web search service is supported by Google Inc.

totopphone